Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2011
02/10/2011US20110034518 Pharmaceutical composition
02/10/2011US20110034517 Selective subtype alpha 2 adrenergic agents and methods for use thereof
02/10/2011US20110034516 Aminopyrazole derivatives
02/10/2011US20110034515 Indole modulators of the alpha 7 nicotinic acetylcholine receptor
02/10/2011US20110034514 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
02/10/2011US20110034513 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production
02/10/2011US20110034512 Indazole Compounds As CCR1 Receptor Antagonists
02/10/2011US20110034511 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
02/10/2011US20110034509 Beta-2-Adrenoreceptor Agonists
02/10/2011US20110034508 Treatment of BDNF-related disorders using laquinimod
02/10/2011US20110034507 Farnesoid x receptor agonists
02/10/2011US20110034506 Triazolopyridine compounds useful as dgat1 inhibitors
02/10/2011US20110034505 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
02/10/2011US20110034504 Agent for preventing and/or treating vascular diseases
02/10/2011US20110034503 Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
02/10/2011US20110034502 Nalmefene prodrugs
02/10/2011US20110034501 Method of restoring the incretin effect
02/10/2011US20110034500 Spiroheterocyclic compounds and their uses as therapeutic agents
02/10/2011US20110034499 Spiroindolines as modulators of chemokine receptors
02/10/2011US20110034498 Dosing regimens for the treatment of cancer
02/10/2011US20110034497 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
02/10/2011US20110034495 Method of Modulating Stress-Activated Protein Kinase System
02/10/2011US20110034494 Reversible inhibition of sperm receptor synthesis for contraception
02/10/2011US20110034489 Solid dosage forms of hiv protease inhibitors
02/10/2011US20110034488 Method of assaying 5-fu
02/10/2011US20110034487 Cxcr3 antagonists
02/10/2011US20110034486 Use of pterocarpans as active anti-cellulite ingredients
02/10/2011US20110034485 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
02/10/2011US20110034484 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
02/10/2011US20110034483 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease
02/10/2011US20110034482 Amine salts of a crth2 antagonist
02/10/2011US20110034481 Novel tetrahydroisoquinoline derivative
02/10/2011US20110034480 Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders
02/10/2011US20110034479 Deuterium-enriched alkyl sulfonamides
02/10/2011US20110034478 Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs
02/10/2011US20110034477 Crystalline Polymorph of Doxazosin Mesylate (Form IV) and Process for Preparation Thereof
02/10/2011US20110034476 Genetic polymorphisms and infertility
02/10/2011US20110034475 1-aza-bicyclo[3.3.1]nonanes
02/10/2011US20110034474 Pyridazinone derivatives
02/10/2011US20110034473 Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases
02/10/2011US20110034472 Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
02/10/2011US20110034471 Novel combinations comprising a phoshodiesterase-5 inhibitor and their use
02/10/2011US20110034470 Inhibitors of JNK
02/10/2011US20110034469 Heterocyclic Compound
02/10/2011US20110034468 Triazolo compounds useful as dgat1 inhibitors
02/10/2011US20110034467 Dihydro-pyrrolopyridine-, dihydro-pyrrolopyridazine- and dihydro-pyrrolopyrimidine-derivatives and use thereof
02/10/2011US20110034466 Novel five-membered ring compound
02/10/2011US20110034465 Processes for the preparation of rivaroxaban and intermediates thereof
02/10/2011US20110034464 Iminopyridine derivatives and use thereof
02/10/2011US20110034463 Type iii secretion inhibitors, analogs and uses thereof
02/10/2011US20110034462 Organic compounds
02/10/2011US20110034461 Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments
02/10/2011US20110034460 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
02/10/2011US20110034459 6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
02/10/2011US20110034458 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
02/10/2011US20110034457 Pyridothiophene Compounds
02/10/2011US20110034456 Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments
02/10/2011US20110034455 Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
02/10/2011US20110034454 Morpholino pyrimidine derivatives and their use in therapy
02/10/2011US20110034453 Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders
02/10/2011US20110034452 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
02/10/2011US20110034451 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
02/10/2011US20110034450 Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof
02/10/2011US20110034449 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
02/10/2011US20110034448 Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
02/10/2011US20110034447 Tdp-43-storing cell model
02/10/2011US20110034446 R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
02/10/2011US20110034444 Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions
02/10/2011US20110034443 Uses of substituted imidazoheterocycles
02/10/2011US20110034442 Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
02/10/2011US20110034441 Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
02/10/2011US20110034440 Homocysteine synthase inhibitor
02/10/2011US20110034439 Acylthiourea compound or salt thereof, and use thereof
02/10/2011US20110034438 Structural mimetics of proline-rich peptides and the pharmaceutical use thereof
02/10/2011US20110034437 Isoxazolines as inhibitors of fatty acid amide hydrolase
02/10/2011US20110034436 spirocyclic aminoquinolnes as gsk-3 inhibitors
02/10/2011US20110034435 Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers
02/10/2011US20110034434 Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
02/10/2011US20110034433 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
02/10/2011US20110034432 Benzamide derivatives and their use as glucokinase activating agents
02/10/2011US20110034431 Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
02/10/2011US20110034430 Phospholipid Gel Compositions for Drug Delivery and Methods of Treating Conditions Using Same
02/10/2011US20110034429 5a-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
02/10/2011US20110034428 Treatment of Prostate Cancer
02/10/2011US20110034426 Method of Preventing Renal Disease and Treating Symptoms Thereof
02/10/2011US20110034425 Method of Treatment for Acute Myelogenous Leukemia
02/10/2011US20110034424 Method for the long term nsaid use
02/10/2011US20110034423 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
02/10/2011US20110034422 Dendrimers for sustained release of compounds
02/10/2011US20110034421 Creatine oral supplementation using creatine hydrochloride salt
02/10/2011US20110034420 Novel crystalline form b of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
02/10/2011US20110034419 Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
02/10/2011US20110034418 Pharmaceutical composition with bisphosphonate
02/10/2011US20110034417 Substituted piperidine compounds and methods of their use
02/10/2011US20110034416 4-pyridinone compounds and their use for cancer
02/10/2011US20110034415 Walnut extracts for nutraceutical applications
02/10/2011US20110034414 Fluoroalkyloxy alkanes, process for production and uses thereof
02/10/2011US20110034413 Novel quercetin derivatives as anti-cancer agents
02/10/2011US20110034412 Visually observable material for medical treatment
02/10/2011US20110034411 Methods and compositions for improving gastrointetinal health